<DOC>
	<DOCNO>NCT02589119</DOCNO>
	<brief_summary>The investigator propose study safety autologous mesenchymal stromal cell transfer use biomatrix ( Gore Fistula Plug ) Phase I study use single dose 20 million cell . 15 adult patient , age 18 year old cryptoglandular fistula enrol . Subjects undergo standard adjuvant therapy include drainage infection placement drain seton . Six week post placement drain seton , seton replace MSC load Gore Fistula Plug ; fistula plug per current clinical practice . The subject subsequently follow fistula response closure 24 month . This autologous product derive patient use patient .</brief_summary>
	<brief_title>Stem Cell Fistula Plug Cryptoglandular Perianal Fistulas ( MSC-AFP )</brief_title>
	<detailed_description>The investigator propose study safety autologous mesenchymal stromal cell transfer use biomatrix ( Gore &amp; # 174 ; Bio-A &amp; # 174 ; Fistula Plug ) Phase I study use single dose 20 million cell . 15 adult patient ( age &amp; gt ; 18 year ) cryptoglandular fistula enrol . Subjects undergo standard adjuvant therapy include drainage infection placement drain seton . Six week post placement drain seton , seton replace MSC load Gore &amp; # 174 ; fistula plug per current clinical practice . The subject subsequently follow fistula response closure 24 month . Study visit Day 1 , Week 2 , Week 4 , Week 8 , Week 12 , Week 24 , Week 52 , Week 104 . This autologous product derive patient use patient .</detailed_description>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Rectal Fistula</mesh_term>
	<criteria>Inclusion Criteria 1 . Males females 1865 year age . 2 . Residents United States . 3 . Singletract , transsphincteric anal fistula cryptoglandular origin . Primary fistula ( previous surgical treatment ) fail previous surgical repair 4 . Have contraindication MR evaluation : e.g . pacemaker magnetically active metal fragment , claustrophobia 5 . Ability comply protocol 6 . Competent able provide write informed consent Exclusion Criteria 1 . Inability give inform consent . 2 . Clinically significant medical condition within six month administration MSCs : e.g . myocardial infarction , active angina , congestive heart failure condition would , opinion investigator , compromise safety patient . 3 . Specific exclusion ; Evidence hepatitis B , C , HIV 4 . History cancer include melanoma ( exception localize skin cancer ) 5 . Investigational drug within thirty ( 30 ) day baseline 6 . A resident outside United States 7 . Pregnant breast feeding . 8 . History clinically significant autoimmunity ( e.g . Crohn 's disease ) previous example fatdirected autoimmunity 9 . Previous allergic reaction perianal fistula plug . 10 . If liposuction technically feasible 11 . Allergic local anesthetic 12 . Pregnant patient try become pregnant . 13 . Nonenterocutaneous tract ( i.e . rectovaginal , enterovesicular ) 14 . Multitract , suprasphincteric extrasphincteric fistula tract extension 15 . Active local infection associate fistula</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cryptoglandular</keyword>
	<keyword>perianal fistula</keyword>
	<keyword>cryptoglandular perianal fistula</keyword>
</DOC>